XNAS
NRXPW
Market cap62mUSD
Jul 11, Last price
0.09USD
1D
-8.07%
1Q
45.40%
IPO
-74.43%
Name
NRX Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
83.26%
Rev. gr., 5y
%
Revenues
0k
Net income
-25m
L-16.66%
CFO
-11m
L-50.88%
Earnings
Aug 12, 2025
Profile
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | 19,704 | 27,587 | 44,401 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (19,704) | (27,587) | (44,401) | |||||
NOPBT Margin | ||||||||
Operating Taxes | (9) | (4,581) | ||||||
Tax Rate | ||||||||
NOPAT | (19,704) | (27,578) | (39,820) | |||||
Net income | (25,126) -16.66% | (30,150) -14.43% | (35,235) -50.87% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 5,911 | 8,122 | 22,702 | |||||
BB yield | -25.55% | -23.31% | -3.11% | |||||
| Debt | ||||||||
Debt current | 1,566 | 9,161 | 8,703 | |||||
Long-term debt | 5,011 | 1,822 | ||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | 5,134 | 4,566 | (9,529) | |||||
| Cash flow | ||||||||
Cash from operating activities | (10,637) | (21,657) | (39,755) | |||||
CAPEX | (3) | (10) | ||||||
Cash from investing activities | (3) | (10) | ||||||
Cash from financing activities | 7,485 | 6,201 | 32,214 | |||||
FCF | (5,712) | (24,575) | (39,820) | |||||
| Balance | ||||||||
Cash | 1,443 | 4,595 | 20,054 | |||||
Long term investments | ||||||||
Excess cash | 1,443 | 4,595 | 20,054 | |||||
Stockholders' equity | (278,258) | (253,063) | (222,992) | |||||
Invested Capital | 261,612 | 250,491 | 240,926 | |||||
ROIC | ||||||||
ROCE | 118.37% | 1,072.59% | ||||||
| EV | ||||||||
Common stock shares outstanding | 10,517 | 7,576 | 65,767 | |||||
Price | 2.20 -52.17% | 4.60 -58.56% | 11.10 -76.78% | |||||
Market cap | 23,138 -33.61% | 34,850 -95.23% | 730,011 -67.45% | |||||
EV | 28,272 | 39,419 | 720,482 | |||||
EBITDA | (19,699) | (27,582) | (44,397) | |||||
EV/EBITDA | ||||||||
Interest | 230 | 120 | 4,581 | |||||
Interest/NOPBT | ||||||||